Big Pharma to Shift Focus to Biotech Firms Such as AEterna Zentaris and ADVENTRX
August 12 2011 - 8:16AM
Marketwired
Shares throughout the biotechnology sector have been exceptionally
volatile of late as developments regarding government approvals,
litigation, and discoveries continue to elicit large movements in
stock prices. The Bedford Report examines the outlook for companies
in the Biotechnology Industry and provides investment research on
AEterna Zentaris, Inc. (NASDAQ: AEZS) (TSX: AEZ) and ADVENTRX
Pharmaceuticals, Inc. (NYSE Amex: ANX). Access to the full company
reports can be found at:
www.bedfordreport.com/AEZS
www.bedfordreport.com/ANX
The importance of maintaining a steady pipeline of drugs to
market is having varied effects on the biotechnology industry.
Analysis by the professional services firm BDO argues that larger
Pharmaceutical firms are increasing reliance on biotech companies
to fill their pipelines, which has been a net positive for small
biotech companies.
According to Thomson Reuters, on average biotech companies in
the NASDAQ Biotechnology Index (NBI) spent $54 million on R&D
in 2010, reflecting a 7 percent decline from 2009.
The Bedford Report releases market research on the Biotechnology
Industry so investors can stay ahead of the crowd and make the best
investment decisions to maximize their returns. Take a few minutes
to register with us free at www.bedfordreport.com and get exclusive
access to our numerous analyst reports and industry
newsletters.
AEterna Zentaris is a late-stage oncology drug development
company currently investigating potential treatments for various
cancers including colorectal, multiple myeloma, endometrial,
ovarian, prostate and bladder cancer.
ADVENTRX Pharmaceuticals is a development-stage specialty
pharmaceutical company focused on in-licensing, developing and
commercializing product candidates for the treatment of cancer.
The Bedford Report provides Market Research focused on equities
that offer growth opportunities, value, and strong potential
return. We strive to provide the most up-to-date market activities.
We constantly create research reports and newsletters for our
members. The Bedford Report has not been compensated by any of the
above-mentioned publicly traded companies. The Bedford Report is
compensated by other third party organizations for advertising
services. We act as an independent research portal and are aware
that all investment entails inherent risks. Please view the full
disclaimer at http://www.bedfordreport.com/disclaimer.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: The Bedford Report Email Contact
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jul 2023 to Jul 2024